Meglumine Diatrizoate (0.66gm) + Sodium Diatrizoate (0.1gm) is a sterile, aqueous, ionic, high-osmolality iodinated contrast medium (HOCM) for intravascular administration. It is a combination of a meglumine salt and a sodium salt of diatrizoic acid, providing a total iodine concentration of approximately 370 mg I/mL. This composition is specifically formulated to reduce the risk of ventricular fibrillation and other cardiac arrhythmias compared to purely sodium-based ionic contrast media, while maintaining good radiographic density. It is widely used in diagnostic imaging procedures across India.
Adult: Dose is highly variable and depends on the type of examination, patient size, and equipment. General ranges: IV Urography: 50-100 mL (approx. 0.5-1.5 mL/kg). Arteriography: 10-40 mL per injection. CT Enhancement: 50-150 mL. MUST BE INDIVIDUALIZED BY THE RADIOLOGIST.
Note: For intravascular use only. Administer as a bolus injection or infusion using sterile technique. Warm to body temperature before use to reduce viscosity. Use immediately after opening vial. Do not mix with other drugs. Flush IV line with normal saline before and after administration. Patient must be under direct medical supervision with resuscitation facilities available.
Diatrizoate salts are radiopaque substances. Iodine (atomic number 53) has a high atomic mass, which effectively absorbs X-rays. When injected into blood vessels, body cavities, or ducts, it attenuates (blocks) X-rays to a much greater degree than surrounding tissues, creating a contrast between the lumen containing the agent and the adjacent tissue. This allows visualization of internal structures during radiographic procedures like angiography, urography, and hysterosalpingography.
Pregnancy: Category D (as per some classifications). Iodinated contrast media cross the placenta and can fetal thyroid. Use only if absolutely essential for maternal diagnosis, after careful risk-benefit assessment. Avoid during first trimester if possible.
Driving: Patients may experience vasovagal reactions, dizziness, or nausea. They should be advised not to drive or operate machinery until these effects have completely resolved, usually on the same day.
| Other Nephrotoxic Drugs (Aminoglycosides, Amphotericin B, NSAIDs, Cisplatin) | Increased risk of contrast-induced nephropathy (CIN). | Major |
| Beta-blockers (especially non-selective like Propranolol) | May potentiate anaphylactoid reactions and make them harder to treat with epinephrine. | Moderate |
| Interleukin-2 (Aldesleukin) | Increased risk of delayed adverse reactions to contrast media. | Moderate |
| Metformin | Risk of lactic acidosis if contrast-induced nephropathy occurs. Metformin should be withheld prior to and after the procedure per protocol. | Major |
| Diuretics (especially Loop Diuretics) | May exacerbate dehydration and increase risk of CIN. | Moderate |
Same composition (Meglumine Diatrizoate (0.66gm) + Sodium Diatrizoate (0.1gm)), different brands: